Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT06097221
Recruiting Not applicable

The Advance Project - Advancing Sleep Timing to Improve Depression

NCT06097221 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2024-04-01
Last updated
2026-02-25

Condition(s) studied

Depression

Investigational drug(s) / intervention(s)

CRT-AdvanceTreatment as usual

CRT-Advance: Psychotherapy with focus on advancing sleep timing, using diaries on sleep and zeitgebers.

Treatment as usual: Treatment as usual in the outpatient psychiatric unit.

Study summary

150 patients with moderate to severe depression, recently discharged from a psychiatric ward and now recieving treatment at an outpatient unit at Mental Health Center Copenhagen, will be randomised in to two groups. A treatment ad usual (TAU) group and an Advance-group. The Advance-group will receive a psychotherapeutic intervention focusing on advancing sleep timing to improve depression.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Moderate to major depression (DSM-V) * Discharge from psychiatric ward within last 30 days * Sleep onset and/or sleep off-set delayed minimum 1 hour based on the last three days, comparred to sleep in the last week of admittance at the psychiatric ward. Exclusion Criteria: * Psychotic depression. * Cognitive problems making participation difficult. * Substance abuse (e.g. alcohol). * Increased suicidal risk.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Mental Health Center Copenhagen Copenhagen Frederiksberg Recruiting

More University Hospital Bispebjerg and Frederiksberg trials in Denmark

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06097221 on ClinicalTrials.gov ↗ ← All trials in Denmark